Connect Biopharma Holdings ADR earnings matched, revenue fell short of estimates
At a glance
- $CNTB today−7.36%last $0.60
- Vs industry peers−6.48 pts6-peer median −0.88% · far behind
- Since Nov 16−3.76%from the first trade after the story
- 52-week range8.3% above low$0.55 – $3.82
- Cash runway~3 mo$16.5M cash ÷ $4.9M/mo burn · 10-Q
- Coverage1 this week1 in 30 days · too few stories to call a pace
Nothing reported about connect biopharma across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: $CNTB came in under the bar; whether it was one rough quarter or a trend is what the guidance tends to answer.
- How the stock is trading: $CNTB -7.36% in the latest session.
- Timing: It came out after the closing bell. The session change shown was settled before the story existed, and the next session is the first that could react.
Where the stock stands
Connect Biopharma Holdings Limi ($CNTB) dropped 7.36% to $0.60 in the latest session. Over the past month it is down 33.8%. It now sits 84% under the 52-week high of $3.82 and 8.3% above the year's low of $0.55, close to the bottom of its range. It has been a volatile year: the high was 6.9 times the low, so moves this size are not unusual for it.
What the filings say
In its latest report (10-Q, filed Nov 16, 2026), $CNTB lost $16.1M over the quarter to Sep 30, 2026 on revenue of $736K (-73.4% QoQ). Operations used $44.0M of cash over the nine months to Sep 30, 2026 — about $4.9M a month — against $16.5M in cash on Sep 30, 2026. At that pace the cash covers about 3 months, which is why financing, asset sales or restructuring tend to come up for companies in this position. Total liabilities were $15.7M against $16.5M of cash on Sep 30, 2026. The company filed an 8-K — the form for material events — on Nov 16, the same day as this story; it is $CNTB's own account and the first thing to read. Figures are as filed with the SEC; the $CNTB page has the full statements.
How much coverage it is getting
This is the only story on Connect Biopharma Holdings Limi in Wook's last 30 days of coverage, so there is no recent run to compare it with.
The bigger picture
Earnings stories turn less on the headline numbers than on how they compare with what analysts expected, and on guidance for next quarter. A beat with weak guidance can land worse than a miss with a raised outlook — markets grade on the curve. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.
Coming up
$CNTB earnings tomorrow — on the calendar well before this story broke. Fresh numbers are close.
What to watch next
For the company's side of it, read its latest SEC filings on the $CNTB page. A US company has to report material news on an 8-K, usually within four business days; foreign issuers use a 6-K. Where several outlets agree is usually the news; where they differ is the angle. Wook AI, at the top of the page, can work out how far $CNTB is from its high or compare this week's coverage with earlier weeks.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on November 17, 2026. $CNTB has moved -3.76% ($0.62 to $0.60). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
